The effectiveness of Moderna’s vaccine against the Coronavirus has been proven 94.5%, which made it enter a feverish race with the “Pfizer” company to contain the pandemic across the world, which has claimed more than 1.2 million lives around the world so far.
The founder of our Moderna Noubar Afeyan
Noubar Afeyan was born to Armenian parents in Lebanon and grew up in Beirut until 13, when his family moved to Montreal, Canada, in 1976.
Noubar Afeyan attended McGill University and graduated with a BA in Chemical Engineering in 1983.
He then continued his education at the Massachusetts Institute of Technology, where he graduated with a Ph.D. in Bioengineering in 1987.
After receiving his doctorate at the age of twenty-four, he established his first small business.
For 10 years, Nubar headed PerSeptive Biosystems, which became the second company in the biosystems business before Perkin Elmer / Applera Corporation acquired it in 1998.
In 1999, Noubar founded Flagship Ventures, an investment fund that invests in companies operating in the health and medical fields.
What about the new vaccine?
Speaking to the press, the American Moderna Company president said that next year we would be able to distribute 500 million doses, indicating that the vaccination of 60% of the world’s population will help limit the spread of the epidemic.
Noubar Afeyan said the US elections did not affect the efforts to provide the vaccine, pointing to the Trump administration’s cooperation in this field on the financial and logistical level, as several different parties funded the vaccine production, as we invested one billion dollars in the search for this vaccine.
Moderna and Innovation
Moderna was founded in 2009 and is headquartered in Cambridge, Massachusetts, and more than 300 people working in it, Moderna’s market capitalization reached $ 22.9 billion on June 8, 2020. On the same date, Stéphane Bancel owned 6.6% of the capital. After the announcement of the success of phase 3, the share of the Moderna laboratory sees its value rise on November 16, 2020, the market capitalization of the laboratory reaches 35.3 billion dollars.
This company invests in more than 100 scientific projects worth $ 30 billion, has registered thousands of patents, and is developing many drugs.
Moderna Therapeutics, which Nubar co-founded and helped lead as chairman of the board of directors, is perhaps the most successful Flagship Ventures startup.
Noubar Afeyan received the “Great Immigrant” Medal from the Carnegie Endowment in 2016, for his outstanding contributions in the field of science. As a foreign American, and in 2017 he received the “Golden Door” award from the International Institute of New England.